Interventional Glaucoma

The company made its CE Mark announcement during the ESCRS Winter Meeting

According to the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields

Standalone, minimally-invasive glaucoma treatments

The partnership establishes a large-scale enrollment platform for research on MicroPulseTransscleral Laser Therapy (TLT)

Prevent Blindness will offer downloadable fact sheets, shareable social media graphics and educational videos for patients

In 2024, the waiting game will pay off for glaucoma specialists who are eager to develop fluency and implement new devices into their practices

Analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with primary open-angle glaucoma

More testing is needed to ensure accuracy across different groups

Results showed that the PAUL Glaucoma Implant is an effective glaucoma drainage device that provides effective IOP lowering, similar to that achieved with the Baerveldt Glaucoma Implant, but with lower rates of complications

The approach to lowering intraocular pressure reduces medication burden without risking graft rejection

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

According to the company, the deal expands its European footprint into Spain and Portugal.

Hundreds of previously-unknown genes could be vital for early detection and treatment.

The open-access tool is the official registry partner of the European Glaucoma Society.

Preliminary results indicate significant improvement for patients and ‘very good safety profile’

Debate continues over the best way to apply treatment option

Surgeons are performing more minimally invasive glaucoma surgeries and fewer trabeculectomy procedures.

Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone, talks about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.

On a recent trip to Togo, West Africa, my colleagues and I taught local ophthalmologists to perform selective laser trabeculoplasty in a model that we hope to see replicated throughout the region.

The findings have potential clinical and public health implications and highlight the greater role of metabolic health status than obesity in IOP elevation, according to the authors.

The procedure can provide prolonged IOP lowering in primary open-angle glaucoma with an excellent safety profile.

Automated AI tool offers offline capability and hope for patients.

Examining the anatomy and physiology may prevent ineffective stent implantation.

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.